RPAM
CRDF icon

Rhenman & Partners Asset Management’s Cardiff Oncology CRDF Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,730
Closed -$1.13M – 100
2014
Q1 		$1.13M Sell
2,730
-48
-2% -$20.8K 0.34% 77
2013
Q4 		$1.15M Buy
+2,778
New +$1.24M 0.45% 76

Other funds holding CRDF

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DIA
Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Rhenman & Partners Asset Management's CRDF Position: Q2 2014 in Review

Rhenman & Partners Asset Management sold out of Cardiff Oncology (CRDF) in Q2 2014, closing a stake of 2,730 shares — an estimated $1.13M sold.

Rhenman & Partners Asset Management first reported a position in CRDF in Q4 2013 and held it in 2 quarters. The position peaked at $1.15M in Q4 2013. 21 funds tracked by Wall St. Rank hold CRDF as of Q2 2014.

  • Rhenman & Partners Asset Management reported no remaining Cardiff Oncology position as of Q2 2014 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 2,730 Cardiff Oncology shares in Q2 2014, an estimated $1.13M.
  • Rhenman & Partners Asset Management first reported a position in Cardiff Oncology in Q4 2013 and held it in 2 quarters.
  • Rhenman & Partners Asset Management's Cardiff Oncology position peaked at $1.15M in Q4 2013.
  • 21 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2014.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2014, filed 31 Jul 2014.